The Food and Drug Administration () has pulled authorization for the monoclonal antibody treatment sotrovimab for use across the northeast in a move signaling the agency fears an upcoming surge fueled of the COVID-19 'stealth' variant.The agency announced Friday that it will no longer authorize the drug, with is manufactured by pharmaceutical giant GlaxoSmithKline (GSK) and Vir Biotechnology, to be used on Covid patients in , , Massachusetts, New Hampshire, Rhode Island, Vermont, New Jersey and New York.These states make up Region 1 and Region 2 as categorized by the U.S. Health and Human Services, and according to most recent data from the Centers for Disease Control and Prevention () are also recording the highest prevalence of the BA.2 'stealth' variant.
Load More
Load More